GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows
94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases achieved complete
GSK's new cancer medicine worked well in patient tests. When a medicine helps many patients, it shows the company may have a valuable product.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.